

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/830,033	10/22/2001	Patrick C. Kung	YALE-025/02US 9303 306577-2036	
7590 12/26/2007 COOLEY GODWARD KRONISH LLP ATTN: Patent Group Suite 1100 777 - 6th Street, NW WASHINGTON, DC 20001			EXAMINER	
			BORIN, MICHAEL L	
			ART UNIT	PAPER NUMBER
			1631	
			MAIL DATE	DELIVERY MODE
			12/26/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		A It At No	A 15 4/-)			
Office Action Summary		Application No.	Applicant(s)			
		09/830,033	KUNG ET AL.			
		Examiner	Art Unit			
		Michael Borin	1631			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
WHIC - Exter after - If NO - Failu Any I	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DAY IN THE MAILING	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be timused and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	lely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status			•			
1)⊠	Responsive to communication(s) filed on <u>05 October 2007</u> .					
2a) <u></u> □	This action is FINAL . 2b)⊠ This action is non-final.					
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Dispositi	ion of Claims					
5)□ 6)⊠ 7)□	Claim(s) 83,84,87 and 88 is/are pending in the 4a) Of the above claim(s) is/are withdraw Claim(s) is/are allowed. Claim(s) 83,84,87,88 is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction and/or	vn from consideration.				
Applicati	on Papers					
10)	The specification is objected to by the Examine The drawing(s) filed on is/are: a) accomplicant may not request that any objection to the Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the Example.	epted or b) objected to by the Eddrawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).			
Priority u	ınder 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.						
Ama-t	M-1					
Attachmen 1) Notice	t(s) e of References Cited (PTO-892)	4) Interview Summary	(PTO-413)			
2) Notic 3) Inform	re of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date	Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	nte			

09/830,033 Art Unit: 1631

DETAILED ACTION

Status of Claims

Claims 83,84,87,88 are pending.

Claim Rejections - 35 USC § 103.

Examiner agrees with applicant's argument that the secondary reference used in the rejection under 35 U.S.C. 103(a) issued in the preceding Office action is predated by effective filing date of the instant application. Therefore, the rejection is withdrawn and is replaced by the following.

Claims 83,84,87,88 are rejected under 35 U.S.C. 103(a) as obvious over Khwaja et al (US Patent 6113907) in view of Lochardt (US patent 6040138).

Khwaja et al is applied as discussed in the previous Office actions.

The reference does not teach use of genomic based bioassays but teaches that use of bioassays is necessary for ensuring quality of a botanical product.

Complex plant materials and extracts exist which have potent, but relatively unpredictable, medicinal properties. These materials are, for the most part, useless in a clinical setting because of the inherent risks involved with treating patients with poorly characterized materials which have no established batch consistency and which may differ widely in composition. Accordingly, there is a need to provide methods for standardizing such complex botanical materials

Application/Control Number:

09/830,033

Art Unit: 1631

The use of gene arrays for content control is well known in the art. See, for example Lochardt (US patent 6040138) describing use of gene arrays for monitoring the expression levels of a multiplicity of preselected genes in the presence of large abundance of non-target nucleic acids. See abstract and col. 2.

Use of known technique, gene arrays, to provide fingerprinting of plant extracts in the method of Khwaja would have been obvious to one skilled in the art.

Enhancing a particular method is a part of the ordinary capabilities of one skilled in the art based upon the teaching of such improvement in other situations. One of ordinary skill in the art would have been capable of applying this known method of use of gene arrays as an enhancement to the method of Khwaja known in the prior art and the results would have been predictable to one of ordinary skill in the art. See Supreme Court's ruling in KSR International Co. v Teleflex Inc..

In addition it will be *prima facie* obvious to one skilled in the art at the time the invention was made to be motivated to use genomic-based assays, such as described in Lochardt, for example, in the method of Khwaja et al to provide control of the content of herbal preparations samples in the method of Khwaja. One of ordinary skill in the art would not be confined by the particular assays taught in the method of Khwaja and will have reasonable expectation of success that genomic-based assays will be equally effective.

Application/Control Number:

09/830,033 Art Unit: 1631

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Borin whose telephone number is (571) 272-0713. The examiner can normally be reached on 9am-5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marjorie Moran can be reached on (571)272-0720. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Michael Borin, Ph.D.

Primary Examiner

Art Unit 1631

mlb